Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting

Amritpal Singh; Aref Al-Kali; James M. Foran; Michelle A. Elliott; Kebede Begna; Talha Badar; Nandita Khera; Farah Fleti; Maymona Abdelmagid; Kareen K. Reichard; Rhett P. Ketterling; Animesh Pardanani; Naseema Gangat; Ayalew Tefferi

doi:10.1002/ajh.26672

Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting

Amritpal Singh, Aref Al-Kali, James M. Foran, Michelle A. Elliott, Kebede Begna, Talha Badar, Nandita Khera, Farah Fleti, Maymona Abdelmagid, Kareen K. Reichard, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	E377-E379
Journal	American journal of hematology
Volume	97
Issue number	10
DOIs	https://doi.org/10.1002/ajh.26672
State	Published - Oct 2022

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26672

Cite this

Singh, A., Al-Kali, A., Foran, J. M., Elliott, M. A., Begna, K., Badar, T., Khera, N., Fleti, F., Abdelmagid, M., Reichard, K. K., Ketterling, R. P., Pardanani, A., Gangat, N., & Tefferi, A. (2022). Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting. American journal of hematology, 97(10), E377-E379. https://doi.org/10.1002/ajh.26672

Singh, A, Al-Kali, A, Foran, JM, Elliott, MA, Begna, K, Badar, T, Khera, N, Fleti, F, Abdelmagid, M, Reichard, KK, Ketterling, RP, Pardanani, A, Gangat, N & Tefferi, A 2022, 'Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting', American journal of hematology, vol. 97, no. 10, pp. E377-E379. https://doi.org/10.1002/ajh.26672

@article{53c71abe6a034d7e953c5993b899dbe4,

title = "Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting",

author = "Amritpal Singh and Aref Al-Kali and Foran, {James M.} and Elliott, {Michelle A.} and Kebede Begna and Talha Badar and Nandita Khera and Farah Fleti and Maymona Abdelmagid and Reichard, {Kareen K.} and Ketterling, {Rhett P.} and Animesh Pardanani and Naseema Gangat and Ayalew Tefferi",

year = "2022",

month = oct,

doi = "10.1002/ajh.26672",

language = "English (US)",

volume = "97",

pages = "E377--E379",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "10",

}

TY - JOUR

T1 - Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q)

T2 - Determinants of response and survival in a real-world setting

AU - Singh, Amritpal

AU - Al-Kali, Aref

AU - Foran, James M.

AU - Elliott, Michelle A.

AU - Begna, Kebede

AU - Badar, Talha

AU - Khera, Nandita

AU - Fleti, Farah

AU - Abdelmagid, Maymona

AU - Reichard, Kareen K.

AU - Ketterling, Rhett P.

AU - Pardanani, Animesh

AU - Gangat, Naseema

AU - Tefferi, Ayalew

PY - 2022/10

Y1 - 2022/10

UR - http://www.scopus.com/inward/record.url?scp=85135939757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85135939757&partnerID=8YFLogxK

U2 - 10.1002/ajh.26672

DO - 10.1002/ajh.26672

M3 - Letter

C2 - 35959963

AN - SCOPUS:85135939757

SN - 0361-8609

VL - 97

SP - E377-E379

JO - American journal of hematology

JF - American journal of hematology

IS - 10

ER -

Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this